Clinical Trial Update: An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia [Phase 1, Phase 2]

View source ↗

Summary

An open-label, single-arm Phase 1/2 clinical trial evaluating CD19/BCMA CAR-T cell therapy for relapsed/refractory warm antibody autoimmune hemolytic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia Warm Antibody Type

Drugs mentioned

• CD19/BCMA CAR-T Cell Therapy

Snippet

Sponsor: Yihao Wang | Conditions: Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING